FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894513469> ?p ?o ?g. }

• W2894513469 endingPage "S78" @default.
• W2894513469 startingPage "S78" @default.
• W2894513469 abstract "The new oral anticoagulants (NOACs) have become an easier and more practical alternative to Warfarin because of the absence of monitoring needed due to their more stable effect over a short period of time, as it’s often needed after cardiac surgery. The aim of this study was to determine the safety of the NOACs in the first three months following cardiac surgery. Between January 2012 and June 2017, 207 patients received NOACs following their cardiac surgery in our center. Patient’s files were reviewed retrospectively. Demographic and perioperative data were collected. Complications that may arise in the first three months post-operatively due to NOACs use were noted. Among the 207 patients studied, 72 % (n=149) were men and the mean age was 70.8 ±1.3 years. As much as 36.7% (n=76) underwent a coronary artery bypass graft (CABG), 38.6% (n=80) had a valve replacement or repair, 22.2% (n=46) underwent both a CABG and a valve replacement and only 2.4% (n=5) had a replacement of the ascending aorta. Ten percent (n=21) were lost to follow-up with an average follow-up period of 7.3 ±1 months. In total, 18 patients (8%) have suffered complications possibly due to the NOAC, but only three (1%) suffered hemorrhagic complications. Among these, only one patient needed transfusions. For the rest, 15 (7%) suffered non-hemorrhagic complications: pleural effusions (n=10), pericardial effusion (n=3), both pleural and pericardial effusions (n=1), thromboembolic event (n=1). Patients received Apixaban, Rivaroxaban or Dabigatran, but the majority were taking Apixaban (n=171, 82.6%). We cannot draw a conclusion as to which NOAC is safest due to the very small number of patients receiving Rivaroxaban and Dabigatran. Finally, 33.3% (n=6) of the complications arose in the first month after the surgery, 38.9% (n=7) in the second month, 16.7% (n=3) in the third month and 11.1% (n=2) after more than 3 months. Based on the results of a previous study done in our center, comparing Warfarin and NOAC, there is no significant difference between the number of complications possibly due to NOAC and those possibly caused by Warfarin. Therefore, NOACs are deemed a safe option after cardiac surgery. A randomized clinical trial would be needed to confirm our findings." @default.
• W2894513469 created "2018-10-05" @default.
• W2894513469 creator A5000266337 @default.
• W2894513469 creator A5020930014 @default.
• W2894513469 creator A5043698704 @default.
• W2894513469 creator A5055253760 @default.
• W2894513469 creator A5059532187 @default.
• W2894513469 creator A5079727789 @default.
• W2894513469 creator A5083365373 @default.
• W2894513469 date "2018-10-01" @default.
• W2894513469 modified "2023-09-28" @default.
• W2894513469 title "AN EVALUATION OF THE SAFETY OF NEW ORAL ANTICOAGULANTS FOLLOWING CARDIAC SURGERY" @default.
• W2894513469 doi "https://doi.org/10.1016/j.cjca.2018.07.293" @default.
• W2894513469 hasPublicationYear "2018" @default.
• W2894513469 type Work @default.
• W2894513469 sameAs 2894513469 @default.
• W2894513469 citedByCount "0" @default.
• W2894513469 crossrefType "journal-article" @default.
• W2894513469 hasAuthorship W2894513469A5000266337 @default.
• W2894513469 hasAuthorship W2894513469A5020930014 @default.
• W2894513469 hasAuthorship W2894513469A5043698704 @default.
• W2894513469 hasAuthorship W2894513469A5055253760 @default.
• W2894513469 hasAuthorship W2894513469A5059532187 @default.
• W2894513469 hasAuthorship W2894513469A5079727789 @default.
• W2894513469 hasAuthorship W2894513469A5083365373 @default.
• W2894513469 hasBestOaLocation W28945134691 @default.
• W2894513469 hasConcept C141071460 @default.
• W2894513469 hasConcept C164705383 @default.
• W2894513469 hasConcept C2776301958 @default.
• W2894513469 hasConcept C2776570981 @default.
• W2894513469 hasConcept C2778249958 @default.
• W2894513469 hasConcept C2778661090 @default.
• W2894513469 hasConcept C2778789114 @default.
• W2894513469 hasConcept C2779161974 @default.
• W2894513469 hasConcept C2779980429 @default.
• W2894513469 hasConcept C2780007028 @default.
• W2894513469 hasConcept C2780638905 @default.
• W2894513469 hasConcept C2781175549 @default.
• W2894513469 hasConcept C31174226 @default.
• W2894513469 hasConcept C71924100 @default.
• W2894513469 hasConceptScore W2894513469C141071460 @default.
• W2894513469 hasConceptScore W2894513469C164705383 @default.
• W2894513469 hasConceptScore W2894513469C2776301958 @default.
• W2894513469 hasConceptScore W2894513469C2776570981 @default.
• W2894513469 hasConceptScore W2894513469C2778249958 @default.
• W2894513469 hasConceptScore W2894513469C2778661090 @default.
• W2894513469 hasConceptScore W2894513469C2778789114 @default.
• W2894513469 hasConceptScore W2894513469C2779161974 @default.
• W2894513469 hasConceptScore W2894513469C2779980429 @default.
• W2894513469 hasConceptScore W2894513469C2780007028 @default.
• W2894513469 hasConceptScore W2894513469C2780638905 @default.
• W2894513469 hasConceptScore W2894513469C2781175549 @default.
• W2894513469 hasConceptScore W2894513469C31174226 @default.
• W2894513469 hasConceptScore W2894513469C71924100 @default.
• W2894513469 hasIssue "10" @default.
• W2894513469 hasLocation W28945134691 @default.
• W2894513469 hasOpenAccess W2894513469 @default.
• W2894513469 hasPrimaryLocation W28945134691 @default.
• W2894513469 hasRelatedWork W110720902 @default.
• W2894513469 hasRelatedWork W1980555552 @default.
• W2894513469 hasRelatedWork W2160586820 @default.
• W2894513469 hasRelatedWork W2785204660 @default.
• W2894513469 hasRelatedWork W2801349979 @default.
• W2894513469 hasRelatedWork W2903462286 @default.
• W2894513469 hasRelatedWork W3107582387 @default.
• W2894513469 hasRelatedWork W3198203860 @default.
• W2894513469 hasRelatedWork W4386253508 @default.
• W2894513469 hasRelatedWork W1570353559 @default.
• W2894513469 hasVolume "34" @default.
• W2894513469 isParatext "false" @default.
• W2894513469 isRetracted "false" @default.
• W2894513469 magId "2894513469" @default.
• W2894513469 workType "article" @default.